A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1123-1129

  Barroso, Paola Andrea ^a   Marco, Jorge Diego ^a,b   Calvopina, Manuel ^a   Kato, Hirotomo ^c   Korenaga, Masataka ^a   Hashiguchi, Yoshihisa ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^c YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

IL 10; IL 4; L. amazonensis

Indexed keywords

ANCER 20; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; MEGLUMINE ANTIMONATE; POLYSACCHARIDE; UNCLASSIFIED DRUG; Z 100;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL VACUOLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DILUTION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT EDEMA; FOOT PAD; GIEMSA STAIN; IC 50; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIASIS; LINEAR REGRESSION ANALYSIS; MACROPHAGE; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PARASITE; PROMASTIGOTE; TH1 CELL; UPREGULATION;

ANIMALS; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; CYTOKINES; DRUG THERAPY, COMBINATION; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LIPIDS; MANNANS; MEGLUMINE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; ORGANOMETALLIC COMPOUNDS; POLYSACCHARIDES;

EID: 34447567288     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm079     Document Type: Article

References (26)

1. Davies CR, Kaye P, Croft SL et al. Leishmaniases: New approaches to disease control. BMJ 2003; 326: 377-82.
2. Sundar S, Rosenkaimer F, Murray HW. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis 1994; 170: 659-62.
3. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J Infect Dis 1997; 175: 1477-9.
4. Avila JL, Biondo F, Monzon H et al. Cutaneous leishmaniasis in mice: Resistance to glucan immunotherapy, either alone or combined with chemotherapy. Am J Trop Med Hyg 1982; 31: 53-9.
5. Adinolfi LE, Bonventre PF. Enhancement of Glucantime therapy of murine Leishmania donovani infection by a synthetic immunopotentiating compound (CP-46,665-1). Am J Trop Med Hyg 1985; 34: 270-7.
6. Smith AC, Yardley V, Rhodes J et al. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2000; 44: 1494-8.
7. Zubairi S, Sanos SL, Hill S et al. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol 2004; 34: 1433-40.
8. Oka H, Sasaki H, Shiraishi Y et al. Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, augments anti-tumor activities of X-ray irradiation against B16 melanoma in association with the improvement of type 1 T cell responses. Biol Pharm Bull 2004; 27: 82-8.
9. Oka H, Emori Y, Ohya O et al. An immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis, Z100, restores the balance of Th1/Th2 cell responses in tumor bearing mice. Immunol Lett 1999; 70: 109-17.
10. Oka H, Shiraishi Y, Sasaki H et al. Antimetastatic effect of an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis strain Aoyama B, Z-100, through the production of interleukin-12. Biol Pharm Bull 2003; 26: 1336-42.
11. Emori Y, Sasaki H, Hayashi Y et al. Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4. Biotherapy 1996; 9: 249-56.
12. Emori Y, Ikeda T, Ohashi T et al. Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol 2004; 85: 2603-13.
13. Afonso, LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61 2952-9.
14. Sypek JP, Chung CL, Mayor SE et al. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 1993; 177: 1797-802.
15. McMahon-Praft D, Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 2004; 201 206-24.
16. Padigel UM, Alexander J, Farrell JP. The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 2003; 171: 3705-10.
17. Kobatake H, Suekane T, Murakami Y et al. Studies on hot water extract of Mycobacterium tuberculosis. I. Structural analyses of polysaccharides. Yakugaku Zasshi 1981; 101: 713-22.
18. Chang KP. Human cutaneous Leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 1986; 209: 1240-2.
19. Lima HC, Bleyenberg JA, Titus RG. A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 1997; 13: 80-2.
20. Korenaga M, Akimaru Y, Shamsuzzaman SM et al. Impaired protective immunity and T helper 2 responses in alymphoplasia (aly) mutant mice infected with Trichinella spiralis. Immunology 2001; 102: 218-24.
21. Taswell C. Limiting dilution assays for the separation, characterization and quantification of biologically active particles and their clonal progeny. In: Pretlow TG, Pretlow TP. eds. Cell Separation: Methods and Selected Applications. New York: Academic Press, 1986; 109-45.
22. Veress B, Abdalla, RE, El Hassan AM. Electron microscope investigations on leishmaniasis in the Sudan: II. Ultrastructural morphology of macrophage-parasite interaction in human and hamster macrophages in vivo. Ann Trop Med Parasitol 1981; 75: 607-13.
23. El Benna J, Han J, Park JW et al. Activation of p38 in stimulated human neutrophils: Phosphorylation of the oxidase component p47phox by p38 and ERK but not by JNK. Arch Biochem Biophys 1996; 334: 395-400.
24. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action. J Infect Dis 1999; 179: 1485-94.
25. Frezard F, Demicheli C, Ferreira CS et al. Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother 2001; 45: 913-6.
26. Toledo VP, Mayrink W, Gollob KJ et al. Immunochemotherapy in American cutaneous leishmaniasis: Immunological aspects before and after treatment. Mem Inst Oswaldo, Cruz 2001; 96: 89-98.